Impact of patients’ and disease characteristics (combined variables) on treatment response and overall survival since the beginning of combined immunotherapy
| Total n = 35 | Responder n = 15 | Non-Responder n = 20 | Response P value | Overall survival P value | |
|---|---|---|---|---|---|
| Combination of TMB [Mut/Mb] and ctDNA [copies/ml] detection3 | |||||
| TMB > 23 Mut/Mb+ ctDNA not detectable | 3 | 3 | 0 | < 0.00011* | 0.0052* |
| TMB > 23 Mut/Mb+ ctDNA detectable | 3 | 3 | 0 | ||
| TMB ≤ 23 Mut/Mb+ ctDNA not detectable | 8 | 5 | 3 | ||
| TMB ≤ 23 Mut/Mb+ ctDNA detectable | 13 | 0 | 13 | ||
| Combination of TMB [Mut/Mb] and ctDNA [copies/ml] increase3 | |||||
| TMB > 23 Mut/Mb+ ctDNA not increasing | 4 | 4 | 0 | < 0.00011* | 0.0322* |
| TMB > 23 Mut/Mb+ ctDNA increasing | 1 | 1 | 0 | ||
| TMB ≤ 23 Mut/Mb+ ctDNA not increasing | 12 | 5 | 7 | ||
| TMB ≤ 23 Mut/Mb+ ctDNA increasing | 9 | 0 | 9 | ||
| Combination of TMB [Mut/Mb] and cell-free DNA [ng/ml]4 | |||||
| TMB > 23 Mut/Mb+ cfDNA decrease > 50% | 3 | 3 | 0 | 0.0011* | 0.0162* |
| TMB > 23 Mut/Mb+ cfDNA stable | 1 | 1 | 0 | ||
| TMB > 23 Mut/Mb+ cfDNA increase > 50% | 1 | 1 | 0 | ||
| TMB ≤ 23 Mut/Mb+ cfDNA decrease > 50% | 3 | 1 | 2 | ||
| TMB ≤ 23 Mut/Mb+ cfDNA stable | 11 | 4 | 7 | ||
| TMB ≤ 23 Mut/Mb+ cfDNA increase > 50% | 7 | 0 | 7 | ||
| Combination of TMB [Mut/Mb] and liver metastases | |||||
| TMB > 23 Mut/Mb+ no liver metastases | 6 | 6 | 0 | < 0.00011* | 0.0182* |
| TMB ≤ 23 Mut/Mb+ no liver metastases | 14 | 5 | 9 | ||
| TMB ≤ 23 Mut/Mb+ liver metastases | 10 | 1 | 9 | ||
| Combination of TMB [Mut/Mb] and sex | |||||
| TMB > 23 Mut/Mb+ male | 6 | 6 | 0 | 0.0021* | 0.0102* |
| TMB ≤ 23 Mut/Mb+ female | 9 | 2 | 7 | ||
| TMB ≤ 23 Mut/Mb+ female | 15 | 4 | 11 | ||
* significant (in bold).
1Exact Chi-Square Test for Trend (Monte Carlo Simulation)
2Log rank test for Trend
3ctDNA measured by tumor-specific variant [copies/ml plasma] at first follow-up after start of combined immunotherapy
4Cell-free DNA [ng/ml plasma] at first follow-up after start of combined immunotherapy